U.S. Markets closed

Glaukos Corporation (GKOS)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
39.34+0.31 (+0.79%)
At close: 04:00PM EDT
39.34 0.00 (0.00%)
After hours: 05:42PM EDT

Glaukos Corporation

229 Avenida Fabricante
San Clemente, CA 92672
United States
949 367 9600

IndustryMedical Devices
Full Time Employees727

Key Executives

NameTitlePayExercisedYear Born
Mr. Thomas William BurnsChairman & CEO1.96M12.84M1961
Mr. Joseph E. GilliamPres & COO991.52k2.43M1977
Mr. Chris M. CalcaterraExec. VP of Global Commercial Operations1M4.34M1960
Dr. Mory Gharib Ph.D.Co-FounderN/AN/AN/A
Mr. Alex R. ThurmanSr. VP & CFON/AN/A1970
Mr. Christopher William LewisVP of Investor Relations & Corp. AffairsN/AN/AN/A
Ms. Diane W. BiagiantiSr. VP & Gen. CounselN/AN/A1960
Ms. Diana A. SchererVP of Compliance & Deputy Gen. CounselN/AN/AN/A
Ms. Michele M. AllegrettoSr. VP of HRN/AN/AN/A
Mr. David S. HaffnerSr. VP of New TechnologiesN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.

Corporate Governance

Glaukos Corporation’s ISS Governance QualityScore as of May 1, 2022 is 7. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 8; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.